Led Crystalys Therapeutics' oversubscribed $130M Series B to advance Phase 3 development of dotinurad for gout.
Crystalys Therapeutics is a biotechnology company specializing in the development and commercialization of therapeutic products, focusing on treatments for serious respiratory disorders and acute radiation
Crystalys Therapeutics is a biotechnology company specializing in the development and commercialization of therapeutic products, focusing on treatments for serious respiratory disorders and acute radiation.